IS Pharma (LON:ISPH) snaps up the rights to Episil
The international speciality pharmaceutical company is on the acquisition trail again!
The Group has announced the acquisition for €1.75 million and royalties of the exclusive rights for Episil, an oncology supportive care product developed by Camurus AB (‘Camurus’), a privately owned Swedish life science company.
Episil is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment. Episil creates a strongly bioadhesive FluidCrystal® film that protects sensitive and…
Previous article Next article
